FORT MYERS — Kieran Murphy, president and CEO of GE Healthcare Life Sciences, joined the board of directors of cancer-laboratory firm NeoGenomics.
In a regulatory filing, the company says Murphy joined the board as part of NeoGenomics' recent acquisition of rival Clarient from GE. As a result of that deal, GE is now a major shareholder of NeoGenomics, owning 32% of the combined companies.
Fort Myers-based NeoGenomics provides cancer testing for oncologists, hospitals and other health care providers through a network of labs in Florida, Tennessee and California. With the acquisition of Clarient, NeoGenomics has become a bigger player in providing pharmaceutical companies with test results from clinical trials. The tests will help drug companies identify the right kinds of therapies for individuals based on their genetic makeup.
GE Healthcare Life Sciences, a unit of corporate behemoth GE, is a $4 billion clinical development and biopharmaceutical manufacturing business. A 25-year veteran of the industry, Murphy earned his bachelor's degree in 1984 from University College, Dublin. He subsequently graduated from the University of Manchester Institute of Science and Technology with a master's degree in marketing.